Study design and patients
METASTATIC CHOLANGIOCARCINOMA
This ongoing, multicenter, single‐arm, phase II study was conducted at 14 hospitals in China. The study was registered on Eligible patients were ≥18 years old, had histologically or cytologically confirmed locally advanced or metastatic cholangiocarcinoma with centrally confirmed This study was accompanied by a retrospective, multicenter, molecular epidemiology study on the frequency of The studies were conducted in accordance with the principles of the Declaration of Helsinki, Good Clinical Practice guidelines, and local applicable regulatory requirements. The study protocols and informed consent were approved by independent ethics committees at participating sites. All participants signed written informed consent forms.